DVAX 8-K: Q3 2025 results and new $100M buyback announced

Rhea-AI Filing Summary

Dynavax Technologies Corporation furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025 and unveiling a new $100 million share repurchase program via an accompanying press release. The press release was furnished as Exhibit 99.1 and provides the detailed results and program terms.

This 8-K indicates the results and buyback authorization were communicated through a press release that is incorporated by reference for informational purposes, while the 8-K itself notes the information is furnished, not filed under the Exchange Act. Shares of DVAX continue to trade on the Nasdaq Global Select Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 04:02 PM Learn about SEC filing dates

0001029142FALSE00010291422025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

    

______________________________________________________

Dynavax Technologies Corporation

(Exact name of Registrant as Specified in Its Charter)

______________________________________________________

Delaware			001-34207			33-0728374
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
2100 Powell Street, Suite 720
Emeryville, CA						94608
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 848-5100

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

DVAX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished herewith:

99.1			Press release dated November 5, 2025 titled "Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program."
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									Dynavax Technologies Corporation
Date:			November 5, 2025			By:			/s/ Kelly MacDonald
									Kelly MacDonald Senior Vice President, CFO

FAQ

What did Dynavax (DVAX) announce in the latest 8-K?

Dynavax announced its financial results for the third quarter ended September 30, 2025 and a new $100 million share repurchase program via a furnished press release.

Which period do the DVAX results cover?

The results cover the third quarter ended September 30, 2025.

How large is Dynavax’s new share repurchase program?

The press release announces a $100 million share repurchase program.

Where can I find the detailed Q3 2025 results and buyback terms for DVAX?

They are contained in Exhibit 99.1, the furnished press release titled “Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program.”

Is the information in this 8-K considered filed or furnished?

The information under Item 2.02 and its exhibit is furnished, not filed, and is not subject to Section 18 liabilities.

What is Dynavax’s trading symbol and exchange?

Dynavax’s common stock trades under the symbol DVAX on the Nasdaq Global Select Market.